Ads
related to: merck & co
Search results
Merck On Track for Largest Percent Decrease Since October 2023 — Data Talk
Morningstar· 6 days agoMerck & Co., Inc. (MRK) is currently at $126.30, down $3.19 or 2.46% --Would be lowest close since April 19, 2024, when it closed at $125.78 --On pace for ...
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence - Merck & Co...
Benzinga· 5 days agoMerck & Co., Inc. MRK is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum...
Merck & Co. sees clear vision to new ophthalmology assets with $3B EyeBio buy
FierceBiotech· 5 days agoMerck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech. Merck will take on a pipeline of vision ...
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Benzinga via Yahoo Finance· 6 days agoEditor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead...
Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
WHTC 1450 Holland· 6 days ago(Reuters) -Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company...
Merck stock climbs as breast cancer Phase 3 trial data meets endpoint By Investing.com
Investing.com· 6 days agoMerck & Co (MRK) announced on Tuesday that its phase 3 KEYNOTE-522 trial evaluating Keytuda...
Merck to buy EyeBio in a deal that could valued at up to $3 billion
Market Watch· 5 days agoannounced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused...
Merck to buy eye drug developer for $1.3B
BioPharma Dive via Yahoo Finance· 5 days agoAn acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Zacks via Yahoo Finance· 7 hours agoThis ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio. Looking at...
Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Simply Wall St. via Yahoo Finance· 2 days agoWhen we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that Merck & Co.
